View Financial HealthCell Bio Human TechLtd 配当と自社株買い配当金 基準チェック /06Cell Bio Human TechLtd配当金を支払った記録がありません。主要情報n/a配当利回り1.5%バイバック利回り総株主利回り1.5%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.お知らせ • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.お知らせ • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩6,280, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.お知らせ • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.分析記事 • Mar 27Additional Considerations Required While Assessing Cell Bio Human TechLtd's (KOSDAQ:318160) Strong EarningsCell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) announced strong profits, but the stock was stagnant. Our analysis...Buy Or Sell Opportunity • Mar 12Now 23% overvaluedOver the last 90 days, the stock has fallen 18% to ₩7,330. The fair value is estimated to be ₩5,970, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to grow by 33% in the next year.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past year.お知らせ • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South KoreaValuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩7,610, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 110% over the past year.分析記事 • Feb 16We Ran A Stock Scan For Earnings Growth And Cell Bio Human TechLtd (KOSDAQ:318160) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,230, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 202% over the past year.分析記事 • Nov 21Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Business Is Trailing The Industry But Its Shares Aren'tWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...Valuation Update With 7 Day Price Move • Nov 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,450, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past year.分析記事 • Oct 16Is Now The Time To Put Cell Bio Human TechLtd (KOSDAQ:318160) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Sep 19Cell Bio Human Tech Co.,Ltd announced that it expects to receive KRW 3.5 billion in funding from Mirae Asset Securities Co., Ltd.Cell Bio Human Tech Co.,Ltd announced a private placement to issue Zero Coupon Series 1 Unsecured Private Equity Convertible Bonds due September 26, 2032 for gross proceeds of KRW 3,500,000,000 on September 18, 2025. The transaction will include participation from new investor Mirae Asset Securities Co., Ltd. (as the trustee of this fund). The transaction has been approved by shareholders, expected to close on September 26, 2025, 100% convertible into 341,930 shares at a fixed conversion price of KRW 10,236 from October 26, 2025 to August 26, 2032, bears zero coupon rate, zero maturity rate and matures on September 26, 2032.New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₩86.5b market cap, or US$62.2m).New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩74.1b market cap, or US$53.4m).分析記事 • Aug 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160) Stock Rockets 30% As Investors Are Less Pessimistic Than ExpectedKOSDAQ:A318160 1 Year Share Price vs Fair Value Explore Cell Bio Human TechLtd's Fair Values from the Community and...Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,080, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 148% over the past year.分析記事 • Jul 21Returns At Cell Bio Human TechLtd (KOSDAQ:318160) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...分析記事 • Jun 16Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩62.1b market cap, or US$45.9m).Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,510, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 86% over the past year.分析記事 • Apr 11Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) 27% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,330, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 32% over the past year.分析記事 • Mar 21Cell Bio Human TechLtd (KOSDAQ:318160) Could Be Struggling To Allocate CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...お知らせ • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Koreaお知らせ • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.分析記事 • Dec 15Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) is...Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,055, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past year.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩3,580, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past year.分析記事 • Oct 23Is Cell Bio Human TechLtd (KOSDAQ:318160) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩27.2b market cap, or US$19.9m).分析記事 • Jun 27Cell Bio Human Tech (KOSDAQ:318160) Seems To Use Debt Rather SparinglyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Jun 08New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩36.5b market cap, or US$26.4m).お知らせ • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.分析記事 • Mar 13Does Cell Bio Human Tech (KOSDAQ:318160) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...決済の安定と成長配当データの取得安定した配当: A318160の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A318160の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Cell Bio Human TechLtd 配当利回り対市場A318160 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A318160)n/a市場下位25% (KR)1.0%市場トップ25% (KR)3.8%業界平均 (Chemicals)1.2%アナリスト予想 (A318160) (最長3年)n/a注目すべき配当: A318160は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A318160は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A318160の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A318160が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 13:16終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cell Bio Human Tech Co.,Ltd 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Hyun Dong SungKB Securities Co., Ltd.
お知らせ • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
お知らせ • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
お知らせ • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩6,280, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.
お知らせ • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
分析記事 • Mar 27Additional Considerations Required While Assessing Cell Bio Human TechLtd's (KOSDAQ:318160) Strong EarningsCell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) announced strong profits, but the stock was stagnant. Our analysis...
Buy Or Sell Opportunity • Mar 12Now 23% overvaluedOver the last 90 days, the stock has fallen 18% to ₩7,330. The fair value is estimated to be ₩5,970, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to grow by 33% in the next year.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past year.
お知らせ • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩7,610, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 110% over the past year.
分析記事 • Feb 16We Ran A Stock Scan For Earnings Growth And Cell Bio Human TechLtd (KOSDAQ:318160) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,230, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 202% over the past year.
分析記事 • Nov 21Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Business Is Trailing The Industry But Its Shares Aren'tWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,450, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past year.
分析記事 • Oct 16Is Now The Time To Put Cell Bio Human TechLtd (KOSDAQ:318160) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Sep 19Cell Bio Human Tech Co.,Ltd announced that it expects to receive KRW 3.5 billion in funding from Mirae Asset Securities Co., Ltd.Cell Bio Human Tech Co.,Ltd announced a private placement to issue Zero Coupon Series 1 Unsecured Private Equity Convertible Bonds due September 26, 2032 for gross proceeds of KRW 3,500,000,000 on September 18, 2025. The transaction will include participation from new investor Mirae Asset Securities Co., Ltd. (as the trustee of this fund). The transaction has been approved by shareholders, expected to close on September 26, 2025, 100% convertible into 341,930 shares at a fixed conversion price of KRW 10,236 from October 26, 2025 to August 26, 2032, bears zero coupon rate, zero maturity rate and matures on September 26, 2032.
New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₩86.5b market cap, or US$62.2m).
New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩74.1b market cap, or US$53.4m).
分析記事 • Aug 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160) Stock Rockets 30% As Investors Are Less Pessimistic Than ExpectedKOSDAQ:A318160 1 Year Share Price vs Fair Value Explore Cell Bio Human TechLtd's Fair Values from the Community and...
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,080, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 148% over the past year.
分析記事 • Jul 21Returns At Cell Bio Human TechLtd (KOSDAQ:318160) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
分析記事 • Jun 16Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩62.1b market cap, or US$45.9m).
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,510, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 86% over the past year.
分析記事 • Apr 11Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) 27% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,330, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 32% over the past year.
分析記事 • Mar 21Cell Bio Human TechLtd (KOSDAQ:318160) Could Be Struggling To Allocate CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
お知らせ • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
お知らせ • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
分析記事 • Dec 15Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) is...
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,055, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past year.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩3,580, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past year.
分析記事 • Oct 23Is Cell Bio Human TechLtd (KOSDAQ:318160) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩27.2b market cap, or US$19.9m).
分析記事 • Jun 27Cell Bio Human Tech (KOSDAQ:318160) Seems To Use Debt Rather SparinglyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Jun 08New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩36.5b market cap, or US$26.4m).
お知らせ • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
分析記事 • Mar 13Does Cell Bio Human Tech (KOSDAQ:318160) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...